The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Maxim lowered the firm’s price target on Silexion Therapeutics (SLXN) to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The ...

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 36.1% of Apogee Therapeutics ...

An institutional investor recently bought a new position in Silexion Therapeutics stock. Wildcat Capital Management LLC bought a new position in shares of Silexion Therapeutics Corp (NASDAQ ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage ...

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and ...